BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $35.00.
BLSM has been the subject of several research reports. Wall Street Zen downgraded shares of BlossomHill Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Leerink Partners raised their price objective on shares of BlossomHill Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, September 21st. HC Wainwright reaffirmed a “buy” rating on shares of BlossomHill Therapeutics in a report on Wednesday, September 30th. Weiss Ratings started coverage on BlossomHill Therapeutics in a research report on Tuesday, November 3rd. They issued a “sell (e-)” rating for the company. Finally, Zacks Research upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research report on Wednesday, September 2nd.
BlossomHill Therapeutics Trading Down 5.5%
BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.36). On average, equities analysts forecast that BlossomHill Therapeutics will post -5.54 EPS for the current year.
About BlossomHill Therapeutics
BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.
See Also
- Five stocks we like better than BlossomHill Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
